HY-14779 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • riociguat  (MedChemExpress)
    93
    MedChemExpress riociguat
    ( A ) H & E stained lung histology. Hyperoxia exposure in the presence of placebo decreased radial alveolar count (RAC) ( B ) and increased mean linear intercept (MLI) ( C ) as compared with normoxia. Administration of <t>riociguat</t> increased RAC and decreased MLI during hyperoxia. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 100 μm.
    Riociguat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/riociguat/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    riociguat - by Bioz Stars, 2023-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) H & E stained lung histology. Hyperoxia exposure in the presence of placebo decreased radial alveolar count (RAC) ( B ) and increased mean linear intercept (MLI) ( C ) as compared with normoxia. Administration of riociguat increased RAC and decreased MLI during hyperoxia. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 100 μm.

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: ( A ) H & E stained lung histology. Hyperoxia exposure in the presence of placebo decreased radial alveolar count (RAC) ( B ) and increased mean linear intercept (MLI) ( C ) as compared with normoxia. Administration of riociguat increased RAC and decreased MLI during hyperoxia. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 100 μm.

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques: Staining

    ( A ) Immunofluorescence staining for von-Willebrand factor (vWF) (green signal). Vascular density (VD) was determined by counting vWF-positive vessels (<50 μm in diameter) on 10 random high-power field (HPF) images from each lung section. ( B ) Hyperoxia exposure in the presence of placebo significantly decreased VD as compared with normoxia group. Administration of riociguat increased VD in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 50 μm.

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: ( A ) Immunofluorescence staining for von-Willebrand factor (vWF) (green signal). Vascular density (VD) was determined by counting vWF-positive vessels (<50 μm in diameter) on 10 random high-power field (HPF) images from each lung section. ( B ) Hyperoxia exposure in the presence of placebo significantly decreased VD as compared with normoxia group. Administration of riociguat increased VD in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 50 μm.

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques: Immunofluorescence, Staining

    ( A , C ) Double immunofluorescence staining for vWF (green signal) and α-SMA (red signal) plus DAPI nuclear stain (blue signal). ( B ) Hyperoxia exposure in the presence of placebo increased muscularization of peripheral pulmonary vessels (<50 μm in diameter) as compared with normoxia group (red arrow). Administration of riociguat decreased muscularized vessels in hyperoxia exposed lungs. ( D ) Hyperoxia increased medial wall thickness (MWT) in presence of placebo as compared with normoxia group. Riociguat administration significantly decreased MWT in hyperoxia group. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 50 μm. ( E ) Double immunofluorescence staining with Ki67 (red arrow) and α-SMA (green signal) plus DAPI nuclear staining (blue signal). ( F ) Hyperoxia exposure in the presence of placebo increased vascular proliferation as compared with normoxia group. Administration of riociguat decreased vascular proliferation. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). ( G ) CTGF gene expression was up-regulated by hyperoxia and it was down-regulated by riociguat. * P < 0.05 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). ( H ) Representative Western blots of CTGF and β-actin. ( I ). Expression of CTGF was increased by hyperoxia, while administration of riociguat decreased CTGF expression in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo (n = 6/group). RA: room air, normaxia; O 2 : hyperoxia; PL: placebo; Rio: riociguat.

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: ( A , C ) Double immunofluorescence staining for vWF (green signal) and α-SMA (red signal) plus DAPI nuclear stain (blue signal). ( B ) Hyperoxia exposure in the presence of placebo increased muscularization of peripheral pulmonary vessels (<50 μm in diameter) as compared with normoxia group (red arrow). Administration of riociguat decreased muscularized vessels in hyperoxia exposed lungs. ( D ) Hyperoxia increased medial wall thickness (MWT) in presence of placebo as compared with normoxia group. Riociguat administration significantly decreased MWT in hyperoxia group. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). Scale bar: 50 μm. ( E ) Double immunofluorescence staining with Ki67 (red arrow) and α-SMA (green signal) plus DAPI nuclear staining (blue signal). ( F ) Hyperoxia exposure in the presence of placebo increased vascular proliferation as compared with normoxia group. Administration of riociguat decreased vascular proliferation. *** P < 0.001 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). ( G ) CTGF gene expression was up-regulated by hyperoxia and it was down-regulated by riociguat. * P < 0.05 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo (n = 6/group). ( H ) Representative Western blots of CTGF and β-actin. ( I ). Expression of CTGF was increased by hyperoxia, while administration of riociguat decreased CTGF expression in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo (n = 6/group). RA: room air, normaxia; O 2 : hyperoxia; PL: placebo; Rio: riociguat.

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques: Double Immunofluorescence Staining, Staining, Expressing, Western Blot

    ( A ) Right ventricular systolic pressure (RVSP) was significantly increased in the hyperoxia + placebo treated group as compared with normoxia group. Riociguat administration significantly decreased RVSP during hyperoxia. *** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo (n = 6/group). ( B ) Right ventricular hypertrophy (RVH), also known as the Fulton’s index, was determined by the weight ratio of right ventricle (RV) to left ventricle + septum (LV + S). Hyperoxia exposed animals in the presence of placebo showed significant RVH as compared with normoxia group. Administration of riociguat decreased RVH in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; ++ P < 0.01 compared with hyperoxia + placebo (n = 6/group).

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: ( A ) Right ventricular systolic pressure (RVSP) was significantly increased in the hyperoxia + placebo treated group as compared with normoxia group. Riociguat administration significantly decreased RVSP during hyperoxia. *** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo (n = 6/group). ( B ) Right ventricular hypertrophy (RVH), also known as the Fulton’s index, was determined by the weight ratio of right ventricle (RV) to left ventricle + septum (LV + S). Hyperoxia exposed animals in the presence of placebo showed significant RVH as compared with normoxia group. Administration of riociguat decreased RVH in hyperoxia exposed lungs. *** P < 0.001 compared with normoxia; ++ P < 0.01 compared with hyperoxia + placebo (n = 6/group).

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques:

    ( A ) Immunostaining for Mac-3, a macrophage marker. ( B ) The alveolar airspace macrophage population was increased by hyperoxia exposure as compared to normoxia. Administration of riociguat decreased macrophage count during hyperoxia. *** P < 0.001 compared with normoxia; ++ P < 0.01 compared with hyperoxia + placebo (n = 6/group). ( C ) Immunostaining for the M1 marker, inducible nitric oxide synthase (iNOS), and M2 markers, chitinase 3-like 3 (Ym1) and resistin-like molecule alpha (RELM-α) showed that in hyperoxia plus placebo lungs, both M1 and M2 polarized macrophages were detected. But, treatment with riociguat decreased only M1 macrophages in hyperoxia-exposed lungs. ( D ) Representative Western blots for NLRP-1, active caspase-1 and active IL-1β. Administration of riociguat decreased hyperoxia-induced lung expression of ( E ) NLRP-1 (*** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo), ( F ) active caspase-1 (*** P < 0.001 compared with normoxia; ++ P < 0.05 compared with hyperoxia + placebo), and ( G ) active IL-1β (* P < 0.05 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo). RA: room air, normoxia; O 2 : hyperoxia; PL: placebo; Rio: riociguat.

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: ( A ) Immunostaining for Mac-3, a macrophage marker. ( B ) The alveolar airspace macrophage population was increased by hyperoxia exposure as compared to normoxia. Administration of riociguat decreased macrophage count during hyperoxia. *** P < 0.001 compared with normoxia; ++ P < 0.01 compared with hyperoxia + placebo (n = 6/group). ( C ) Immunostaining for the M1 marker, inducible nitric oxide synthase (iNOS), and M2 markers, chitinase 3-like 3 (Ym1) and resistin-like molecule alpha (RELM-α) showed that in hyperoxia plus placebo lungs, both M1 and M2 polarized macrophages were detected. But, treatment with riociguat decreased only M1 macrophages in hyperoxia-exposed lungs. ( D ) Representative Western blots for NLRP-1, active caspase-1 and active IL-1β. Administration of riociguat decreased hyperoxia-induced lung expression of ( E ) NLRP-1 (*** P < 0.001 compared with normoxia; + P < 0.05 compared with hyperoxia + placebo), ( F ) active caspase-1 (*** P < 0.001 compared with normoxia; ++ P < 0.05 compared with hyperoxia + placebo), and ( G ) active IL-1β (* P < 0.05 compared with normoxia; +++ P < 0.001 compared with hyperoxia + placebo). RA: room air, normoxia; O 2 : hyperoxia; PL: placebo; Rio: riociguat.

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques: Immunostaining, Marker, Western Blot, Expressing

    Riociguat significantly increased cGMP concentration in hyperoxia-exposed rats as compared with placebo treated hyperoxic rats. * P < 0.05 compared with hyperoxia + placebo (n = 4/group).

    Journal: PLoS ONE

    Article Title: Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth

    doi: 10.1371/journal.pone.0199927

    Figure Lengend Snippet: Riociguat significantly increased cGMP concentration in hyperoxia-exposed rats as compared with placebo treated hyperoxic rats. * P < 0.05 compared with hyperoxia + placebo (n = 4/group).

    Article Snippet: Riociguat was obtained from Medchemexpress (Monmouth Junction, NJ).

    Techniques: Concentration Assay